Hyloris Pharmaceuticals Sa · EURONEXT:HYL
Hyloris Pharmaceuticals Sa — Investor Presentation (April 2026)
42 slides from Hyloris Pharmaceuticals Sa's investor presentation, Apr 1, 2026
Slide 1: Where others stop, we start and add value
Where others stop, we start and add value Reinventing Existing Medicines Nice to meet you!
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, “presentation” means this document, oral presenta
Slide 3: Pharma needs faster & more affordable innovation
Pharma needs faster & more affordable innovation The traditional way thousands only a of drug candidates are fraction in the pipeline make it to market worldwide Slow Expensive Risky
Slide 4: Our Mission
Our Mission We add value through Reinventing Existing Medications for unmet patient needs worldwide
Slide 5: We think different by unlocking the hidden potential of existing medicines
We think different by unlocking the hidden potential of existing medicines Agile Affordable Efficient
Slide 6: Reinvent existing & Invent new medicines
Reinvent existing & Invent new medicines REFORMULATING REPURPOSING NCE Improve DOSAGE FORM and/or change Repurpose existing medicine for a ROUTE of administration of existing NEW therapeutic INDICATION (use) medicines New Chemical Entity Target to be MORE EFFECTIVE – MORE NEW PRODUCT – NEW FIELD usi
Slide 7: Reinvent existing & Invent new medicines
Reinvent existing & Invent new medicines REFORMULATING REPURPOSING NCE Facilitating A catalyst for co – development & growth with Third Parties
Slide 8: We always improve therapy outcomes & provide benefits
We always improve therapy outcomes & provide benefits for: Patients Physicians Payers
Slide 9: Driving faster innovation
Our Value Proposition: Driving faster innovation Reducing Time-to-Market, Cost & Clinical Burden average Traditional model for NCE’s & Biologics 15years up to Approved molecules Hyloris - model 7 years Reduction time (pre)clinical development Needs of Stakeholders taken into account Leverage public
Slide 10: FDA's 505(b)(2) pathway as the engine
FDA’s 505(b)(2) pathway (or equivalent) as the engine Added value to healthcare system Addressing clear unmet needs Technical feasibility Clear scientific & medical rationale Fast market adoption Approved, well-known molecules ≤ 7 years to market Maximized ROI Defined regulatory pathway Large potent
Slide 11: A strong chain for shared success
A strong chain for shared success Approval to R&D & CMC pipeline Own Ideas Tech transfer to CDMO (puring process) Scientific Clinical R&D Academic Collaboration Regulatory Industry Collaboration Terms with collaboration TIMELINE Agreed value Scientific Revenu from global sharing with Partnerships Fi
Slide 12: A broad, high-value development portfolio driving sustainable growth
A broad, high – value development portfolio driving sustainable growth Commercial Partnerships (Products Launched) 30+ products 3 Maxigesic IV Sotalol IV Podofilox Gel (value added / non-opioid analgesic) (value added / cardiovascular) (high barrier generic / infectious diseases ) In Development 28
Slide 13: Our Product Portfolio: Strategic Focus Groups for Growth
Our Product Portfolio (as publicly announced) 3 Strategic Focus Groups for Growth
Slide 14: 3 Strategic Focus Groups for Growth
Our Product Portfolio (as publicly announced) 3 Strategic Focus Groups for Growth MAVERICKS CORE DRIVERS PROMISING SEEDS A high-potential product backed A catalyst product building a An early-stage product pending with clinical evidence and strong recurring revenue base at clinical validation: signi
Slide 15: Our Product Portfolio: 3 Strategic Focus Groups
Our Product Portfolio (as publicly announced) Product Fiches will be shared separately 3 Strategic Focus Groups for Growth MAVERICKS CORE DRIVERS PROMISING SEEDS HY-094 (Iron Deficiency Anemia) Maxigesic® IV HY-083 (Idiopathic Rhinitis) Milrinone ER Sotalol IV HY-095 (Equine Gastric Ulcers) Miconazo
Slide 16: Key Products Funnel
Key Products Funnel
Slide 17: Broad, innovative cardiovascular portfolio
Broad, innovative cardiovascular portfolio Clinical Regulatory Filing and Target Product Route/Form Indication Formulation Development approval Market UP TO 7 YEARS Sotalol IV IV Atrial Fibrillation Partnered in the U.S. with AltaThera U.S. Aspirin IV IV Acute Coronary Syndrome WW Milrinone ER Oral
Slide 18: Other value-added portfolio
Other value-added portfolio Clinical Regulatory Filing and Target Product Route/Form Indication Formulation Development approval Market UP TO 7 YEARS Maxigesic® IV IV Post-operative pain Co-development with AFT Pharmaceuticals WW Podofilox Gel Topical Ext. genital/perianal warts Partnered in the U.S
Slide 19: Other value-added portfolio, cont'd
Other value-added portfolio, cont’d Clinical Regulatory Filing and Target Product Route/Form Indication Formulation Development approval Market UP TO 7 YEARS Injection Equine Gastric Ulcer Syndrome HY-095 (PPI) LAI WW Pantoprazole RTU Injection GERD and EE WW WW ex. U.S. Ondansetron ER Tablet Nausea
Slide 20: What sets us apart: Product Selection – ROI – Risk Profile
What sets us apart: Product Selection – ROI – Risk Profile Center of Excellence CMO search – efficiency for R&D and Regulatory Cost development Impressive KOL network Worldwide Worldwide partner/distribution Strategic Insights to indentify unmet medical needs network Patient-centric appr
Slide 21: Our 5 Strategic Pillars Of Excellence
Our 5 Strategic Regulatory & Development Pillars Of Portfolio Focus & Value Prioritization Excellence Excellence Concentrate capital and management attention on assets with the highest Drive efficient development pathways through strong formulation, CMC, clinical, in Execution probability of regulat
Slide 22: Product Portfolio Fiches
Product Portfolio Fiches
Slide 23: HY-094 (Iron Deficiency Anemia) MAVERICK
HY-094 (Iron Deficiency Anemia) MAVERICK Worldwide Markets Intravenous (IV) Iron for Iron Deficiency Anemia (NCE) ABOUT HY-094 is a next-generation intravenous (IV) iron product candidate and new chemical entity (NCE) for the treatment of iron deficiency anemia in adults. It is designed to address l
Slide 24: HY-094 (Iron Deficiency Anemia)
HY-094 (Iron Deficiency Anemia) Indication: Iron Deficiency Anemia (IDA) Global Intravenous Iron Drugs Market Size 2023 to 2034 (USD Billion) 9 • Innovative NCE injectable iron therapy designed to overcome limitations of 8 current treatments for better convenience and tolerability 7 • Targeting glob
Slide 25: Global By Design: Our diversification Solutions & Markets
Global By Design: Our diversification Solutions & Markets
Slide 26: Products launched today
Products launched today Number of Products 3 North America Europe ◉ Cardiovascular ◉ Non-opioid analgesic ◉ Non-opioid analgesic 1 ◉ Anti-infectious APAC ◉ Non-opioid analgesic Africa ◉ Non-opioid analgesic 26/3/2026 – PR/Annual Results 2025 Powered by Bing © Australian Bureau of Statistics, GeoName
Slide 27: Expected product launches in coming years
Expected product launches in coming 3 years Europe Number of Products 7 ◉ Non-opioid analgesic North America ◉ Anti-infectious ◉ Cardiovascular ◉ Electrolyte and mineral ◉ Non-opioid analgesic 1 ◉ Bleeding ◉ Anti-infectious ◉ Dentistry APAC ◉ Mental- and behaviour ◉ Non-opioid analgesic ◉ Bleeding ◉
Slide 28: Patents granted today
Patents granted today Europe Patent North America ◉ Cardiovascular CIS 43 ◉ Cardiovascular ◉ Non-opioid analgesic ◉ Non-opioid analgesic ◉ Non-opioid analgesic ◉ Anti-infectious ◉ Anti-infectious ◉ Dentistry 0 ◉ Dentistry ◉ Urology ◉ Bleeding MENA ◉ Mental- and behaviour ◉ Oncology ◉ Non-opioid anal
Slide 29: Patents granted + patent applications
Patents granted + patent applications* (and continuous expansion) Patent+Application Europe 60 North America ◉ Cardiovascular CIS ◉ Cardiovascular ◉ Non-opioid analgesic ◉ Non-opioid analgesic ◉ Non-opioid analgesic ◉ Anti-infectious 1 ◉ Anti-infectious ◉ Dentistry ◉ Dentistry ◉ Urology ◉ Mental- an
Slide 30: Our Strategy
Our Strategy Multiple shots on goal Lower risk as we start 30+ Potential from Innovative, existing value-added Multiple drug drugs game changer, near term filings candidates ** geared for growth ≤ €7 million average cost to market* 3 products commmercialised Ambition to become the ≤ 7 years to marke
Slide 31: Symphonies sound monumental but we behave like a jazz band
Symphonies sound monumental but we behave like a jazz band: agile in every note, bold in every move
Slide 32: Where others stop, we go that extra mile
Where others stop, we go that extra mile. To cover unmet pharma needs. With compliance as our backbone, we give existing medicines a second life through patient-centric, advanced innovation. We do so together with our partner network. Aiming for trustworthy collaboration and responsible growth.
Slide 33: Highlights 2025
ghts 2025 HP ili ja oe ee - | om a j CHyloris en ah
Slide 34: 2025: A landmark year
2025: A landmark year A year of bold moves and breaktrough milestones Suramin IV (NCE) HY-095 undisclosed molecule 6 NEW hitting our ambitious 30+ portfolio target Methanobactin (NBE) Ondansetron ER PRODUCTS Pantoprazole IV Iron IV (NCE) XTRAZA Expanding our global Colonis: UK Huons: South Korea AFT
Slide 35: Financial Highlights 2025
Operating Income Operating income amounted to €8,832 thousand in 2025, compared to €10,043 thousand in 2024, primarily reflecting a lower contribution from Financial Highlights 2025 non-recurring milestone income, partly offset by robust growth in royalty revenues. Royalty income increased by 15% ye
Slide 36: 2026: Milestones For The Year
2026: Milestones For The Year Key clinical, regulatory and commercial milestones CLINICAL REGULATORY COMMERCIAL Clinical trial starts Submissions Launch / deals Phase 1: Arbor-101, Pantoprazole IV, PTX-252 Dofetilide IV Tranexamic acid RTU launch Phase 2: Miconazole-DB in Bacterial Vaginosis Phospha
Slide 37: The Hyloris Share
The Hyloris Share 2026 Stijn Van Rompay 28% Thomas Jacobsen 43% Scorpiaux BV Nick Reunbrouck Pieter Van Rompay 12% Other Holders 3% 6% 8% Total number of outstanding voting rights (denominator) 28,000,374 For founders: Based on transparency notifications and latest denominator; Total number of secur
Slide 38: Hyloris at a glance
Hyloris at a glance Specialty High Yield Founded Pharma Company Low Risk 2012 Listed 2020 Broad HQ Quoted on pipeline Liège Euronext (Belgium) Brussels 30+ products HYL 55 People Strong network 30 men & knowhow 25 women 12 countries 13 nationalities 4 continents
Slide 39: Our Core Values
Our Core Values Entrepreneurship Professional Excellence Passion & Integrity & Drive Accountability
Slide 40: The team behind the science & route to market
The team behind the science & route to market Stijn Van Rompay Thomas Jacobsen Dietmar Aichorn Christophe Maréchal Ann De Jaeger Co-CEO & Founder Co-CEO, CBDO & Founder COO CFO CLO >20 years of experience in leadership >20 years of experience in pharma. >20 years of experience in various >25 years o
Slide 41: Our Strength
Our People Our Strength
Slide 42: Value Starts Here
Value Starts Here Hyloris Pharmaceuticals SA - 2026 HQ: Boulevard Patience Et Beaujonc N°3/1 4000 Liège, Belgium +32(0)4 346 02 07 contact@hyloris.com investorrelations@hyloris.com
Hyloris Pharmaceuticals — Investor Presentation (April 2026) on 6ix